

Chapter 238

Photochemotherapy and Photodynamic Therapy

Herbert Hönigsmann, Rolf-Markus Szeimies, & Robert Knobler

REFERENCES

1. Pathak MA, Fitzpatrick TB: The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. *J Photochem Photobiol B Biol* **14**:3, 1992
2. Parrish JA et al: Photochemotherapy of psoriasis with oral methoxsalen and long wave ultraviolet light. *N Engl J Med* **291**:1207, 1974 [PMID: 4422691]
3. Wolff K et al: Photochemotherapy for psoriasis with orally administered methoxsalen. *Arch Dermatol* **112**: 943-950, 1976 [PMID: 820269]
4. Fischer T, Alsins J: Treatment of psoriasis with trioxsalen baths and dysprosium lamps. *Acta Derm Venereol* **56**:383, 1976 [PMID: 78625]
5. Dall'Acqua F et al: Principles of psoralen photosensitization. In: *The Fundamental Bases of Phototherapy*, edited by H Hönigsmann, G Jori, AR Young. Milan, OEMF SpA, 1996, p.1,
6. Schmitt IM et al: Photobiology of psoralens. In: *The Fundamental Bases of Phototherapy*, edited by H Hönigsmann, G Jori, AR Young. Milan, OEMF SpA, 1996 p. 17
7. Averbeck D: Recent advances in psoralen phototoxicity mechanism. *Photochem Photobiol* **50**:859, 1989 [PMID: 2696993]
8. Hönigsmann H: Phototherapy for psoriasis. *Clin Exp Dermatol* **6**:343, 2001 [PMID: 17912756]
9. Wolff K et al: Phototesting and dosimetry for photochemotherapy. *Br J Dermatol* **96**:1, 1977 [PMID: 320992]
10. Ibbotson SH, Dawe RS, Farr PM: The effect of methoxsalen dose on ultraviolet-A-induced erythema. *J Invest Dermatol* **116**:813, 2001 [PMID: 11348476]
11. Ibbotson SH, Farr PM: The time-course of psoralen ultraviolet A (PUVA) erythema. *J Invest Dermatol* **113**:346, 1999 [PMID: 10469332]
12. Halpern SM et al: Guidelines for topical PUVA: A report of a workshop of the British photodermatology group. *Br J Dermatol* **142**:22, 2000 [PMID: 10651690]
13. Melski JW et al: Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial. *J Invest Dermatol* **68**:328, 1977 [PMID: 864273]
14. Henseler T et al: Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: A cooperative study among 18 European centres. *Lancet* **i**:853, 1981
15. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol* **62**:114, 2010
16. Anonymous: British Photodermatology Group guidelines for PUVA. *Br J Dermatol* **130**:246, 1994
17. Radakovic S et al: Failure of short-term psoralen and ultraviolet A light maintenance treatment to prevent early relapse in patients with chronic recurring plaque-type psoriasis. *Photodermatol Photoimmunol Photomed* **25**:90, 2009
18. Morison WL: Phototherapy and photochemotherapy. *Adv Dermatol* **7**:255, 1992 [PMID: 1739583]
19. Stern RS, Laird N: Photochemotherapy Follow-up Study: The carcinogenic risks of treatments for severe psoriasis. *Cancer* **73**:2759, 1994 [PMID: 8194017]
20. Marcil I, Stern RS: Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: Nested cohort crossover study. *Lancet* **358**:1042, 2001 [PMID: 11589933]
21. Molin L, Larkö O: Cancer induction by immunosuppression in psoriasis after heavy PUVA treatment [letter]. *Acta Derm Venereol* **77**:402, 1997 [PMID: 9298142]
22. Van de Kerkhof PC, De Rooij MJ: Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and ciclosporin treatment: Response to long-term acitretin maintenance. *Br J Dermatol* **136**:275, 1997

23. Hönigsmann H, Wolff K: Results of therapy for psoriasis using retinoid and photochemotherapy (RePUVA). *Pharmacol Ther* **40**:67, 1989 [PMID: 17912756]
24. Nijsten TEC, Stern RS: Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: A nested cohort study. *J Am Acad Dermatol* **49**:644, 2003 [PMID: 14512910]
25. Ortonne JP et al: An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. *J Eur Acad Dermatol Venereol* **19**:556, 2005 [PMID: 16164708]
26. Lebwohl M: Combining the new biologic agents with our current psoriasis armamentarium. *J Am Acad Dermatol* **49**(Suppl. 2):S118, 2003
27. Gilchrist BA et al: Oral methoxsalen photochemotherapy of mycosis fungoides. *Cancer* **38**:683, 1976 [PMID: 824045]
28. Baron ED, Stevens SR: Phototherapy for cutaneous T-cell lymphoma. *Dermatol Ther* **16**:303, 2003 [PMID: 14686973]
29. Zhang C, Duvic M: Retinoids: Therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. *Dermatol Ther* **16**:322, 2003 [PMID: 14686975]
30. Singh F, Lebwohl MG: Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series. *J Am Acad Dermatol* **51**:570, 2004 [PMID: 15389192]
31. Tanew A, Hönigsmann H: Ultraviolet B and psoralen plus UVA phototherapy for cutaneous T-cell lymphoma. *Dermatol Ther* **4**:38, 1997
32. Stadler R et al: Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. *Blood* **92**:3578, 1998 [PMID: 9808550]
33. Stadler R: Optimal combination with PUVA: rationale and clinical trial update. *Oncology (Williston Park)* **2**(Suppl. 1):29, 2007
34. Querfeld C, Rosen ST, Kuzel TM: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. *Arch Dermatol* **141**:305, 2005 [PMID: 15781671]
35. Morison WL: *Phototherapy and Photochemotherapy of Skin Disease*, 2nd edition. New York, Raven, 1991, p. 148
36. Tzaneva S et al: 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: A randomized crossover trial. *Br J Dermatol* **162**:655, 2010
37. Honig B, Morison WL, Karp D: Photochemotherapy beyond psoriasis. *J Am Acad Dermatol* **31**:775, 1994 [PMID: 7929924]
38. Christophers E et al: PUVA-treatment of urticaria pigmentosa. *Br J Dermatol* **98**:701, 1978 [PMID: 678458]
39. Lange-Wantzin G, Thomsen K: PUVA-treatment in lymphomatoid papulosis. *Br J Dermatol* **107**:687, 1982
40. Kerker BJ, Huang CP, Morison WL: Photochemotherapy of generalized granuloma annulare. *Arch Dermatol* **126**:359, 1990 [PMID: 2310208]
41. Taylor CR, Hawk JLM: PUVA treatment of alopecia areata partialis, totalis and universalis: Audit of 10 years' experience at St. John's Institute of Dermatology. *Br J Dermatol* **133**:914, 1995 [PMID: 8547044]
42. Kerscher M et al: Treatment of localised scleroderma with PUVA bath photochemotherapy. *Lancet* **343**:1233, 1994 [PMID: 7909904]
43. Scharfetter-Kochanek K et al: PUVA therapy in disabling pansclerotic morphea of children. *Br J Dermatol* **132**:830, 1995
44. Volc-Platzer B et al: Photochemotherapy improves chronic cutaneous graft-versus-host disease. *J Am Acad Dermatol* **23**:220, 1990 [PMID: 2212117]
45. Kunz M et al: Treatment of severe erythrodermic acute graft-versus-host disease with photochemotherapy. *Br J Dermatol* **144**:901, 2001 [PMID: 11298559]
46. Kwok YK, Anstey AV, Hawk JL: Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. *Clin Exp Dermatol* **27**:104, 2002 [PMID: 11952699]
47. Yones SS et al: Randomized double blind trial of treatment of vitiligo. *Arch Dermatol* **143**:578, 2007
48. Hönigsmann H: Mechanisms of phototherapy and photochemotherapy for photodermatoses. *Dermatol Ther* **16**:23-27, 2003
49. Hönigsmann H: Polymorphous light eruption. *Photodermatol Photoimmunol Photomed* **24**(3):155, 2008
50. Roelandts R: Diagnosis and treatment of solar urticaria. *Dermatol Ther* **16**:52, 2003

51. Tanew A, Ferguson J: Phototherapy and photochemotherapy of the idiopathic photodermatoses. In: *Dermatological Phototherapy and Photodiagnostic Methods*, 2nd edition, edited by Krutmann J, Hönigsmann H, Elmets C., Berlin, Springer, 2009, p. 119
52. Roelandts R: Photo(chemo)therapy and general management of erythropoietic protoporphyria. *Dermatology* **190**:330, 1995 [PMID: 7655119]
53. Ullrich SE: Does exposure to UV radiation induce a shift to a Th-2-like immune reaction? *Photochem Photobiol* **64**:254, 1996 [PMID: 8760564]
54. Morrey JD et al: In vivo activation of human immunodeficiency virus type 1 long terminal repeat by UV type A (UV-A) light plus psoralen and UV-B light in the skin of transgenic mice. *J Virol* **65**:5045, 1991 [PMID: 1908029]
55. Zmudzka BZ et al: Medical UV exposures and HIV activation. *Photochem Photobiol* **64**:246, 1996 [PMID: 8760563]
56. Morison WL: PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. *Photochem Photobiol* **64**:267, 1996 [PMID: 8760566]
57. Menon K et al: For the National Psoriasis Foundation. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* **62**:291, 2010
58. Hönigsmann H: Psoralen photochemotherapy—Mechanisms, drugs, toxicity. *Curr Probl Dermatol* **15**:52, 1986 [PMID: 17912756]
59. Nyfors A, Dahl-Nyfors B, Hopwood D: Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): Findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. *J Am Acad Dermatol* **14**:43, 1986 [PMID: 3950113]
60. Calzavara-Pinton PG et al: Antinuclear antibodies are not induced by PUVA treatment with uncomplicated psoriasis. *J Am Acad Dermatol* **30**:955, 1994 [PMID: 8188886]
61. Dunnick JK et al: Tumors of the skin in the HRA/Skh mouse after treatment with 8-methoxypsoralen and UVA radiation. *Fundam Appl Toxicol* **16**:92, 1991 [PMID: 2019354]
62. Stern RS, Liebman EJ, Vakeva L: Oral psoralen and ultraviolet – A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. *J Natl Cancer Inst* **90**:1278, 1998 [PMID: 9731734]
63. Henseler T et al: Skin tumors in the European PUVA study. Eight year follow-up of 1643 patients treated with PUVA for psoriasis. *J Am Acad Dermatol* **16**:108, 1987 [PMID: 3805379]
64. Lim JL, Stern RS: High levels of ultraviolet B exposure increase the risk of nonmelanoma skin cancer in psoralen and ultraviolet A-treated patients. *J Invest Dermatol* **124**:505, 2005 [PMID: 15737190]
65. Murase JE, Lee EE, Koo J: Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. *Int J Dermatol* **44**:1016, 2005
66. Stern RS, Members of the Photochemotherapy Follow-up Study: Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A (PUVA) radiation and ultraviolet B radiation. *N Engl Med J* **322**:1093, 1990 [PMID: 2320078]
67. Wolff K, Hönigsmann H: Genital carcinomas in psoriasis patients treated with photochemotherapy. *Lancet* **337**:439, 1991 [PMID: 1671465]
68. Aubin F et al: Genital squamous cell carcinoma in men treated by photochemotherapy. A cancer registry-based study from 1978 to 1998. *Br J Dermatol* **144**:1204, 2001 [PMID: 11422042]
69. Stern RS: The PUVA follow-up study. The risk of melanoma in association with long-term exposure to PUVA. *J Am Acad Dermatol* **44**:755, 2001 [PMID: 11312420]
70. Stern RS, Nichols KT, Vakeva LH: Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. *N Engl J Med* **336**:1041, 1997 [PMID: 9091799]
71. Wolff K: Should PUVA be abandoned? [editorial]. *N Engl J Med* **336**:1090, 1997 [PMID: 9091807]
72. Forman AB et al: Long-term follow-up of skin cancer in the PUVA-48 cooperative study. *Arch Dermatol* **125**:515, 1989
73. Chuang TY et al: PUVA and skin cancer: A historical cohort study on 492 patients. *J Am Acad Dermatol* **26**:173, 1992
74. Young AR: Photochemotherapy and skin carcinogenesis: A critical review. In: *The Fundamental Bases of Phototherapy*, edited by H Hönigsmann, G Jori, AR Young. Milan, OEMF, 1996, p. 77
75. Hannuksela-Svahn A et al: Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. *Br J Dermatol* **141**:497, 1999 [PMID: 10583054]

76. Hannuksela-Svahn A et al: Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. *J Am Acad Dermatol* **40**:694, 1999 [PMID: 10321595]
77. Young AR: Carcinogenicity of UVB phototherapy assessed. *Lancet* **345**:1431, 1995
78. Stern RS: Ocular lens findings in patients treated with PUVA. Photochemotherapy follow-up study. *J Invest Dermatol* **103**:534, 1994 [PMID: 7930678]
79. Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: A 25-year prospective study. *J Am Acad Dermatol* **57**:23, 2007
80. Stern RS, Lange R: Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. *Arch Dermatol* **127**:347, 1991 [PMID: 1998364]
81. Edelson R et al: Treatment of cutaneous T-cell lymphoma. *N Engl J Med* **316**: 297, 1987 [PMID: 3543674]
82. Demierre MF, Foss F, Koh H: Proceedings of the International Consensus Conference on cutaneous T-cell lymphoma (CTCL): Treatment recommendations. *J Am Acad Dermatol* **36**:460, 1997 [PMID: 9091480]
83. Trautinger F et al: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. *Eur J Cancer* **42**:1014, 2006 [PMID: 16574401]
84. Knobler E et al: Extracorporeal photochemotherapy—The Columbia Presbyterian experience. *Photodermatol Photoimmunol Photomed* **18**:232, 2002 [PMID: 12390664]
85. Scarisbrick J: Extracorporeal photopheresis: What is it and when should it be used? *Clin Exp Dermatol* **34**:757 2009
86. Knobler R et al: Extracorporeal photopheresis: Past, present, and future. *J Am Acad Dermatol* **61**:652, 2009
87. McKenna KE et al: Evidence-based practice of photopheresis 1987-2001: A report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. *Br J Dermatol* **154**:7, 2006
88. Knobler RM et al: Parenteral administration of 8-methoxypsoralen in photopheresis. *J Am Acad Dermatol* **28**:580, 1993 [PMID: 8463458]
89. Maeda A et al: Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T-cells. *J Immunol* **174**:5968, 2005 [PMID: 15879089]
90. Maeda A et al. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: Generation of IL-10 and induction of regulatory T cells. *J Immunol* **181**:5956, 2008
91. Knobler R, Girardi M: Extracorporeal photochemoimmunotherapy in cutaneous Tcell lymphomas. *Ann N Y Acad Sci* **941**:123, 2001 [PMID: 11594566]
92. Zic JA et al: Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. *J Am Acad Dermatol* **35**:935, 1996 [PMID: 8959953]
93. Gottlieb SL et al: Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. *J Am Acad Dermatol* **35**:946, 1996 [PMID: 8959954]
94. Shapiro M et al: Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet: A for a patient with refractory stage IVa. *J Am Acad Dermatol* **47**:956, 2002 [PMID: 12451388]
95. Greinix HT et al: Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. *Blood* **92**:3098, 1998 [PMID: 9787144]
96. Foss FM et al: Prospective study of extracorporeal photopheresis in steroidrefractory or steroid-resistant extensive chronic graft-versus-host disease: Analysis of response and survival incorporating prognostic factors. *Bone Marrow Transplant* **35**:1187, 2005 [PMID: 15852025]
97. Greinix HT et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graftversus-host disease. *Haematologica* **91**: 405, 2006
98. Dall'Amico R, Murer L: Extracorporeal photochemotherapy: A new therapeutic approach for allograft rejection. *Transfus Apher Sci* **26**:197, 2002 [PMID: 12126206]
99. Kumlien G et al: Photopheresis for the treatment of refractory renal graft rejection. *Transplantation* **79**:123, 2005 [PMID: 15714180]
100. Pass HI: Photodynamic therapy in oncology: Mechanisms and clinical use. *J Natl Cancer Inst* **85**:443-456, 1993[Archana3]
101. Kennedy JC, Pottier RH: Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. *J Photochem Photobiol B* **14**:275-292, 1992

102. Fritsch C et al: Ex vivo application of α -aminolevulinic acid induces high and specific porphyrin levels in human skin tumors: Possible basis for selective photodynamic therapy. *Photochem Photobiol* **66**:114-118, 1997
103. Penning LC, Dubbelman TM: Fundamentals of photodynamic therapy: Cellular and biochemical aspects. *Anticancer Drugs* **5**:139-146, 1994
104. Jones CM et al: Photodynamic therapy in the treatment of Bowen's disease. *J Am Acad Dermatol* **27**:979-982, 1992
105. Dougherty TJ: Photoradiation therapy for cutaneous and subcutaneous malignancies. *J Invest Dermatol* **77**:122-124, 1981
106. Oseroff AR et al: A dose ranging study, of photodynamic therapy with porfimer sodium (Photofrin[®]) for treatment of basal cell carcinoma. *Lasers Surg Med* **38**:417-426, 2006
107. Lui H, Anderson RR: Photodynamic therapy in dermatology. *Arch Dermatol* **128**:1631-1636, 1992
108. Weinstein GD et al: Low-dose photofrin II photodynamic therapy of psoriasis. *Clin Res* **39**:509A, 1991
109. Boehncke WH, Elshorst-Schmidt T, Kaufmann R: Systemic photodynamic therapy is a safe and effective treatment for psoriasis. *Arch Dermatol* **136**:271-272, 2000
110. Szeimies RM, Sassy T, Landthaler M: Penetration potency of topical applied α -aminolevulinic acid for photodynamic therapy of basal cell carcinoma. *Photochem Photobiol* **59**:73-76, 1994
111. Fritsch C et al: Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism. *Arch Dermatol Res* **288**:517-521, 1996
112. Szeimies RM et al: Topical photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic keratoses: A first clinical study. *Dermatology* **192**:246-251, 1996
113. Jeffes EW et al: Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. *Arch Dermatol* **133**:727-732, 1997
114. Morton CA et al: Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. *Br J Dermatol* **135**:766-771, 1996
115. Basset-Seguín N et al: Topical methyl aminolaevulinic photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: A 5 year randomized trial. *Eur J Dermatol* **18**:547-553, 2008
116. Rhodes LE et al: Photodynamic therapy using topical methyl aminolevulinic vs. surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. *Arch Dermatol* **140**:17-23, 2004
117. Braathen LR et al: Guidelines on the use of photodynamic therapy (PDT) for non-melanoma skin cancer—An international consensus. *J Am Acad Dermatol* **56**:125-143, 2007
118. Zane C et al: Photodynamic therapy with methylaminolevulinic acid as a valuable treatment option for unilesional cutaneous T-cell lymphoma. *Photodermatol Photoimmunol Photomed* **22**:254, 2006 [PMID: 16948827]
119. Weinstein GD, McCullough JL, Jeffes EW: Photodynamic therapy (PDT) of psoriasis with topical delta aminolevulinic acid (ALA): A pilot dose ranging study. *Photodermatol Photoimmunol Photomed* **10**:92, 1994
120. Radakovic-Fijan S et al: Topical aminolaevulinic acid based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. *Br J Dermatol* **152**:279, 2005 [PMID: 15727639]
121. Schleyer V et al: Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. *J Eur Acad Dermatol Venereol* **20**:823, 2006 [PMID: 16898905]
122. Karrer S et al: Topical photodynamic therapy for localized scleroderma. *Acta Dermatol Venereol* **80**:26, 2000 [PMID: 10721828]
123. Karrer S et al: Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. *Br J Dermatol* **151**:776, 2004 [PMID: 15491416]
124. Frank RG, Bos JD: Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. *Genitourin Med* **72**:70, 1996 [PMID: 8655176]
125. Karrer S et al: Epidermodysplasia verruciformis treated using topical 5-aminolevulinic acid photodynamic therapy. *Br J Dermatol* **140**:935, 1999 [PMID: 10354037]
126. Stender IM et al: Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: Randomized double-blind trial. *Lancet* **355**:963, 2000 [PMID: 10768434]
127. Asilian A, Davami M: Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World

- cutaneous leishmaniasis: A placebo-controlled, randomized clinical trial. *Clin Exp Dermatol* **31**:634, 2006 [PMID: 16780497]
128. Hongcharu W et al: Topical ALA-photodynamic therapy for the treatment of acne vulgaris. *J Invest Dermatol* **115**:183, 2000 [PMID: 10951234]
129. Pollock B et al: Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: A study of clinical efficacy and mechanism of action. *Br J Dermatol* **151**:616, 2004 [PMID: 15377348]
130. Bhardwaj SS, Rohrer TE, Arndt K: Lasers and light therapy for acne vulgaris. *Semin Cutan Med Surg* **24**:107, 2005 [PMID: 16092799]
131. Nybaek H, Jemec GBE: Photodynamic therapy in the treatment of rosacea. *Dermatology* **211**:135, 2005 [PMID: 16088160]
132. Dover JS et al: Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. *Arch Dermatol* **141**:1247, 2005 [PMID: 16230562]
133. Gold MH et al: Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. *Dermatol Surg* **32**:795, 2006 [PMID: 16792644]
134. Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S: Photodynamic photorejuvenation. *Dermatol Surg* **28**:742, 2002 [PMID: 12174070]
135. Touma DJ, Gilchrist BA: Topical photodynamic therapy: A new tool in cosmetic dermatology. *Semin Cutan Med Surg* **22**:124, 2003 [PMID: 12877231]
136. Orringer JS et al: Molecular effects of photodynamic therapy for photoaging. *Arch Dermatol* **144**: 1296-1302, 2008
137. Kohl E et al: Aesthetic effects of topical photodynamic therapy. *J Eur Acad Dermatol* DOI: 10.1111/j.1468-3083.2010.03625.x, 2010